Dow Jones

39 069,59

0,01%

DAX

Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Inotek Pharmaceuticals Corp. (delisted) (ITEK)
Inotek Pharmaceuticals Corp. (delisted) (ITEK) Actualités

ITEK

INOTEK PHARMACEUTICALS CORP (ITEK)

Inotek Pharmaceuticals Corp. (delisted)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ITEK

1 2 3 4 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
14/02/2018	23h51	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
31/01/2018	20h31	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
25/01/2018	23h14	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
25/01/2018	22h16	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
19/01/2018	23h03	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
19/01/2018	19h52	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
16/01/2018	22h09	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
11/01/2018	22h32	Edgar (US Regulatory)	Amended Securities Registration (section 12(b)) (8-a12b/a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
22/12/2017	22h52	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
04/12/2017	22h13	Edgar (US Regulatory)	Proxy Statement - Merger or Acquistion (definitive) (defm14a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
20/11/2017	23h02	Edgar (US Regulatory)	Proxy Soliciting Materials (revised) (prer14a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
08/11/2017	14h03	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
12/10/2017	23h20	Business Wire	Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy C...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
12/10/2017	23h08	Edgar (US Regulatory)	Proxy Statement - Merger or Acquistion (preliminary) (prem14a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
18/09/2017	22h49	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
13/09/2017	00h06	Business Wire	INSERTING & REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of Fi...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
12/09/2017	22h15	Business Wire	Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Ther...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
03/08/2017	22h01	Business Wire	Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
07/07/2017	22h01	Business Wire	Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson & Provides Corporat...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
10/05/2017	13h00	Business Wire	Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
08/05/2017	22h05	Business Wire	Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision & Ophthalmology (A...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
26/04/2017	22h48	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
11/04/2017	13h00	Business Wire	Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
23/03/2017	12h47	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
16/03/2017	12h43	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
16/03/2017	12h00	Business Wire	Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
27/02/2017	13h00	Business Wire	Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
25/02/2017	02h22	PR Newswire (US)	URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Im...	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
24/02/2017	13h00	Business Wire	Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)
10/02/2017	15h00	Business Wire	Inotek Pharmaceuticals to Present at the BIO CEO and Investor Conference	NASDAQ:ITEK	Inotek Pharmaceuticals Corp. (delisted)